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Background: Genome-scale studies of psoriasis have been used to identify genes of potential relevance to disease
mechanisms. For many identified genes, however, the cell type mediating disease activity is uncertain, which has
limited our ability to design gene functional studies based on genomic findings.
Methods: We identified differentially expressed genes (DEGs) with altered expression in psoriasis lesions (n = 216
patients), as well as candidate genes near susceptibility loci from psoriasis GWAS studies. These gene sets were
characterized based upon their expression across 10 cell types present in psoriasis lesions. Susceptibility-associated
variation at intergenic (non-coding) loci was evaluated to identify sites of allele-specific transcription factor binding.
Results: Half of DEGs showed highest expression in skin cells, although the dominant cell type differed between
psoriasis-increased DEGs (keratinocytes, 35%) and psoriasis-decreased DEGs (fibroblasts, 33%). In contrast, psoriasis
GWAS candidates tended to have highest expression in immune cells (71%), with a significant fraction showing
maximal expression in neutrophils (24%, P < 0.001). By identifying candidate cell types for genes near susceptibility
loci, we could identify and prioritize SNPs at which susceptibility variants are predicted to influence transcription
factor binding. This led to the identification of potentially causal (non-coding) SNPs for which susceptibility variants
influence binding of AP-1, NF-κB, IRF1, STAT3 and STAT4.
Conclusions: These findings underscore the role of innate immunity in psoriasis and highlight neutrophils as a cell
type linked with pathogenetic mechanisms. Assignment of candidate cell types to genes emerging from GWAS
studies provides a first step towards functional analysis, and we have proposed an approach for generating
hypotheses to explain GWAS hits at intergenic loci.
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Psoriasis is a chronic disease in which interactions bet-
ween immune cells and keratinocytes (KCs) lead to deve-
lopment of plaque-like lesions with adherent silvery
scales. To better understand molecular mechanisms
underlying this process, investigators have applied gen-
ome-scale technologies, such as expression profiling and
genome-wide association studies (GWAS) [1-4]. This has
provided a wealth of new data, although there remain
many gaps between the individual genes uncovered from
these approaches and our current understanding of pso-
riasis pathogenesis [5]. In this respect, a key challenge is* Correspondence: wswindel@umich.edu
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unless otherwise stated.that both approaches, expression profiling and GWAS, es-
sentially provide pointers to individual genes, but do not
necessarily provide indication as to which cell type serves
as the main context for a gene’s disease activity [3,6-8].
This challenge is compounded by the complex and multi-
cellular nature of psoriasis, with lesions arising from the
interactions among a number of heterogeneous cell types,
such as T-cells, dendritic cells, macrophages and KCs [9].
Even from an optimistic standpoint, therefore, it must be
acknowledged that genome-scale approaches will provide
us only with pieces of the puzzle (i.e., individual genes)
[1,2]. Putting this puzzle together will require conceptual
bridges that connect genetics with biology, and this, in
turn, is almost certain to require a high quality mappingl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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type(s).
There has been historical tension between the idea of
psoriasis as a skin disease, affecting mostly KCs, and the
understanding of psoriasis as an (auto)-immune disease,
involving cells from the adaptive and/or innate immune
systems [10-14]. Early on, psoriasis was viewed primarily
as a skin disease, and was treated entirely with topical
agents, such as coal tar derivatives, salicylic acid and
corticosteroids [15,16]. The understanding of psoriasis
as an immune disease, however, was bolstered by the
efficacy and widespread adoption of immunosuppressant
drugs (e.g., cyclosporine) [17]. This has been abundantly
reinforced, more recently, by the success of biologic
therapies designed to block inflammatory cytokines or
inhibit lymphocyte activation (e.g., etanercept, alefacept
and efaluzimab) [18]. The progression in psoriasis treat-
ments thus reflects increased emphasis on immune cells,
and T-cells in particular, as central players in psoriasis
pathogenesis [16]. Still, when transplanted onto immu-
nodeficient mice, uninvolved skin from psoriasis patients
develops into psoriasis lesions, whereas normal skin
from normal subjects does not [19]. This suggests that a
skin-intrinsic defect is required for development of pso-
riasis lesions, and it is possible that this underlying skin
abnormality initiates or partly drives the inflammatory
response and aggregation of immune cells within lesions
[20]. A balanced view of psoriasis, therefore, appears
most justifiable, in which psoriasis is understood as a cu-
taneous/immune hybrid disease, dependent upon patho-
logical interactions between KCs and immune cells, as
well as interactions among the immune cells themselves.
Moreover, insofar as immune cells are accepted as pri-
mary drivers of psoriasis, the relative contributions of
the innate and adaptive immune systems remains un-
clear [14,21]. Macrophages, NK cells and neutrophils,
for example, are all present in psoriasis lesions and
reinforce inflammatory cascades by releasing cytokines
while activating other inflammatory cell types, including
T-cells [22-24].
Genome-scale approaches can provide insights into
the relative importance of KCs and the balance between
innate and adaptive immunity in psoriasis pathogenesis
[1-4]. Studies of genome-wide expression have proven
informative with regard to the composition of psoriasis
lesions and have been used to assess which inflammatory
cells show increased abundance relative to uninvolved
skin [3,6]. One prior meta-analysis of microarray data,
for instance, showed that genes with elevated expression
in psoriasis lesions were enriched with genes expressed
at high levels in KCs, as expected, but also enriched with
genes expressed at high levels in cell types from the
adaptive (T-cells) and innate immune systems (macro-
phages and NK-cells) [3]. GWAS findings, moreover,have the potential to identify cell types acting as insti-
gators in the disease process [7,8,25]. Along these lines,
the importance of the adaptive immune system in pso-
riasis has long been supported by strong genetic associa-
tions involving genes functioning in antigen presentation
(i.e., HLA-C) [1,2]. It was especially notable, therefore,
when a recent psoriasis GWAS meta-analysis uncovered
associations that implicated genes functioning within the
innate immune system (e.g., DDX58, KLF4, ZC3H12C,
CARD14 and CARM1) [26]. Alongside these results,
nearly all GWAS studies to date have also uncovered
some loci near genes with KC-specific functions (e.g.,
LCE3D), thus implicating disease mechanisms intrinsic
to the skin [11-13]. Authors have often interpreted such
results to support the relevance of particular cell types
in psoriasis, but no systematic analyses have been carried
out to associate GWAS findings with cell types specific
to skin, innate immunity, or adaptive immunity. As we
move into the post-GWAS era, however, such analyses
will be necessary and can indeed provide a first step to-
wards functional studies aimed at understanding how
risk variants contribute to disease mechanisms [7].
The goal of this study is to extend findings from pso-
riasis transcriptome and GWAS analyses to establish
connections between genes and disease-relevant cell
types. We provide an updated meta-analysis of the pso-
riasis transcriptome, based upon data from prior stu-
dies that have utilized a common microarray platform
(n = 216 patients total) [6,27-31]. Using these data, we
identify differentially expressed genes (DEGs) within pso-
riasis lesions, assign a candidate cell type to each DEG,
and assess overall trends with respect to the assigned cell
types. Following the same strategy, we identify genes asso-
ciated with psoriasis susceptibility loci [26,32,33], assign
cell types to each candidate gene, and characterize overall
trends. Our findings provide new insights into the relative
role of KCs, adaptive immunity and innate immunity in
psoriasis, while providing a first step towards post-GWAS
functional analyses. To illustrate this latter point, we de-
velop a systematic approach for functional interpretation
of intergenic susceptibility loci. The approach requires as-
signment of candidate cell types to candidate genes and
identifies potentially causal (non-coding) SNPs at which
variation is predicted to influence transcription factor
binding.
Results
Meta-analysis identifies 1904 differentially expressed
genes (DEGs) with significantly altered expression in
psoriasis lesions (n = 216 patients)
We evaluated gene expression in lesional (PP) and unin-
volved (PN) skin samples across a large patient cohort
(n = 216 patients). Our analysis included 16358 skin-
expressed genes for which expression was detectable in
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patients. In total, we identified 1019 PP-increased DEGs
(FC > 1.50 and FDR < 0.05; Additional file 1) along with
885 PP-decreased DEGs (FC < 0.67 and FDR < 0.05;
Additional file 2). Expression of PP-increased DEGs was,
on average, detected above background in 94% of PP sam-
ples and 84% of PN samples (Additional file 3, Parts A
and B). Likewise, expression of PP-decreased DEGs was,
on average, detected above background in 86% of PP sam-
ples and 94% of PN samples (Additional file 3, Parts C
and D). These percentage values were significantly large in
comparison to all other genes included in our analysis
(P ≤ 0.02; Additional file 3). We were unable to identify
any DEGs for which expression was decreased in all 216
patients. However, we identified 13 DEGs for which ex-
pression was increased in all 216 patients (IL36G, KYNU,
RHCG, ATP12A, HPSE, CCL20, PRSS27, FUT2, SER-
PINB13, WNT5A, LOC100996579, C20orf24 and SOX7).
These may be regarded as hallmark genes with univer-
sally or near-universally increased expression in psoriasis
lesions.
Psoriasis DEGs overlap significantly with genes altered in
diverse skin diseases (squamous cell carcinoma, atopic
dermatitis, Mediterranean spotted fever eschars)
Comparison of psoriasis DEGs to genes altered in a di-
verse set of skin diseases revealed strong correspondence
(Figure 1). The strongest correspondence was observed
for squamous cell carcinoma, atopic dermatitis and Medi-
terranean spotted fever eschars, although significant cor-
respondence was also detected for other skin conditions
as well (e.g., acne, wounding, nickel contact dermatitis;
Figure 1 and Additional file 4). For these conditions, PP-
increased DEGs overlapped significantly with genes ele-
vated in diseased skin, while conversely, PP-decreased
DEGs overlapped significantly with genes repressed in dis-
eased skin (Figure 1 and Additional file 4). We next com-
pared psoriasis DEGs to those genes altered in microarray
experiments in which cultured KCs (or skin equivalents)
were treated with cytokines. This highlighted the IL-20R1/
IL-20R2 receptor complex cytokines (IL-20, IL-19 and
IL-24) as those best able to induce expression of PP-
increased DEGs and repress expression of PP-decreased
DEGs (Figure 1 and Additional file 4).
Psoriasis DEGs were disproportionately elevated or
repressed in cultured KCs following RNAi treatments
targeting differentiation-associated genes or lncRNAs
(Additional file 4). PP-increased DEGs were elevated in
KCs following knockdown of the anti-differentiation
lncRNA ANCR (P = 5.8 × 10−25, GSEA) [34], but de-
creased following knockdown of the pro-differentiation
gene TP63 (P = 1.2 × 10−25, GSEA) [35]. PP-decreased
DEGs, moreover, were elevated in KCs following knock-
down of the pro-differentiation gene MLL2 (P = 9.4 × 10−36,GSEA) [36]. Finally, inspection of psoriasis DEGs revealed
trends related to DNA methylation [37]. PP-increased
DEGs were disproportionately associated with hypo-me-
thylated DNA sites in psoriasis lesions (P = 4.8 × 10−13,
GSEA), while conversely, PP-decreased DEGs were dispro-
portionately associated with hyper-methylated DNA sites
(P = 6.8 × 10−15, GSEA).
Assignment of psoriasis DEGs and GWAS candidates to
cell types present in lesional skin
Psoriasis is a complex disease involving interactions
among multiple cell types from skin and the adaptive/
innate immune systems [9]. For psoriasis DEGs, it is un-
clear which cell types underlie shifts in gene expression,
and similarly, it is often uncertain which cell types me-
diate disease-associated effects of genes near suscepti-
bility loci [3,6,7]. To address these issues, we compiled a
large database of microarray samples from 10 different
cell types: primary KCs, fibroblasts, CD4+ T-cells, NK
cells, CD8+ T-cells, B cells, macrophages, monocytes,
dendritic cells (DCs) and neutrophils (Additional file 5).
For each cell type, a large number of microarray samples
was obtained, with no fewer than 118 samples for any
one cell type (Additional file 5).
The database was used to assign a candidate cell type
to each human gene based upon the gene’s expression
level across the 10 cell types. For each gene, we identi-
fied the cell type for which the gene’s median expression
was highest, provided that expression was detected in at
least 10% of microarray samples (P < 0.05, Wilcoxon
signed rank test) [38]. No assignment was made if a
gene’s expression was not detected in at least 10% of
microarray samples for any cell type (P < 0.05). After
assignments were made, we assessed trends among PP-
increased and PP-decreased DEGs, as well as among
candidate genes identified from psoriasis GWAS studies
(Figure 2).
Psoriasis-increased DEGs are enriched with genes
expressed at high levels in KCs and macrophages
Approximately 50% of PP-increased DEGs were assigned
to KCs or fibroblasts, while the remaining 50% were
assigned to immune cell types. PP-increased DEGs were
enriched with respect to the number of genes assigned
to KCs and macrophages (P < 0.05; Fisher’s Exact Test;
Figures 2 and 3). These trends were further supported
by rank-based analyses, which showed that KC- and
macrophage-assigned genes tended to have elevated ex-
pression in PP versus PN skin (P ≤ 2.2 × 10−20; GSEA;
Additional file 6, Part A). A non-parametric bootstrap
analysis also indicated that PP-increased DEGs, on aver-
age, had higher-than-expected expression and detection
frequency only for KCs and macrophages, but not for
other cell types (Additional file 7). 35% of PP-increased
Figure 1 Gene set enrichment analysis: Psoriasis DEGs overlap significantly with genes altered in other skin diseases and in cytokine-treated
KCs. We identified 1019 PP-increased DEGs and 885 PP-decreased DEGs (n = 216 patients) and evaluated how these genes were altered in other
skin diseases or experiments with cytokine-treated KCs. (A) Comparison with skin diseases. Psoriasis DEGs were compared to ranked gene lists
generated from microarray studies comparing diseased skin samples with normal or uninvolved skin. Barplots show GSEA area statistics calculated
for each comparison (i.e., area between foreground and background detection rate curves; see parts C and D). Positive area statistics indicate that
psoriasis DEGs are disproportionately elevated in a given skin disease, while negative statistics indicate that psoriasis DEGs are disproportionately
repressed. The analysis was performed with respect to PP-increased DEGs and PP-decreased DEGs, and comparisons are ranked according to the
maximum p-value from the two analyses (Wilcoxon rank sum test). The top-ranked 10 comparisons are shown (of 51 included in our screen).
(B) Comparison with cytokine-treated KCs. The analysis was repeated with respect to ranked gene lists generated from microarray experiments in
which cultured KCs were treated with cytokines. Left margin labels list the concentration of cytokine (per mL) and the duration of treatment. The
top-ranked 10 comparisons are shown (of 46 included in our screen). Most experiments were performed with primary NHEKs (** denotes experiments
performed using reconstituted epidermis). (C) GSEA analysis of psoriasis-increased DEGs and squamous cell carcinoma (SCC). Genes were ranked
according to how strongly they were increased in SCC as compared to normal skin (GEO series GSE7553). The figure shows the cumulative overlap
between psoriasis-increased DEGs and this ranked gene list. Significance of this overlap is proportional to the area between this curve and the diagonal
(i.e., grey region). Yellow hashmarks (top) denote the 100 DEGs most strongly elevated in psoriasis lesions (i.e., highest PP/PN fold-change). (D) GSEA
analysis of psoriasis-decreased DEGs and SCC. Yellow hashmarks (top) denote the 100 DEGs most strongly repressed in psoriasis lesions (i.e., lowest
PP/PN fold-change).
Swindell et al. BMC Medical Genomics 2014, 7:27 Page 4 of 22
http://www.biomedcentral.com/1755-8794/7/27DEGs (358/1019) were expressed more highly in KCs than
any other cell type (Figure 2). Examples of KC-assigned
genes strongly elevated in psoriasis lesions included SER-
PINB4, SPRR2C and SERPINB3 (Additional file 8). Con-
sistent with heightened KC proliferation, KC-assigned PP-
increased DEGs were frequently associated with organelle
fission, cell division and the cell cycle (data not shown).
Approximately 8% of PP-increased DEGs (82/1019) wereassigned to macrophages (Figure 2), the strongest exam-
ples of which included KYNU, ADAMDEC1 and CXCL13
(Additional file 8). These and other macrophage DEGs
were commonly associated with response to biotic stimu-
lus, immune response and programmed cell death (data
not shown).
PP-increased DEGs were not significantly enriched
with respect to several inflammatory cell types, such as
Figure 2 Assignment of psoriasis DEGs and GWAS candidates to cell types present in lesional skin. Human genes were assigned to one
of 10 cell types present in psoriasis lesions. Genes were assigned to the cell type for which median expression was highest, provided that the
gene’s expression was detected in at least 10% of microarray samples for that cell type (P < 0.05, Wilcoxon signed-rank test). If a gene’s expression
was not detected with respect to at least 10% of microarray samples for any cell type, no assignment was made (i.e., unassigned). Pie charts show
the percentage of PP-increased DEGs (top), PP-decreased DEGs (middle) and GWAS candidates (bottom) that were either unassigned or allocated
to one of the 10 cell types. Magenta labels denote those cell types for which the number of assigned genes was significantly large in comparison
to all skin-expressed genes (PP-increased and PP-decreased DEGs) or in comparison to all genes represented on the Affymetrix Human Genome
U133 Plus 2.0 array platform (GWAS candidates) (one asterisk, P < 0.05; two asterisks, FDR < 0.05; Fisher’s Exact Test).
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among 438 DEGs elevated more than 2-fold in psoriasis
lesions (rather than 1.5-fold), there was significant en-
richment for neutrophil-assigned genes (64/438 DEGs;
P = 0.031, Fisher’s Exact Test). For other inflammatory
cell types, however, lack of enrichment is likely due to
the fact that DEGs include only genes showing the most
consistent expression patterns among psoriasis lesions,excluding those genes associated with more variable
patterns, such as those that might be associated with
infiltration by certain immune cells [3,6]. To test this
idea, we calculated cell type-specific signatures for each
of the 216 patients, which allowed us to quantify the
degree to which genes showing specific expression in a
given cell type were elevated or repressed within indivi-
dual patients [3]. Consistent with our expectation, genes
Figure 3 Cluster analysis of 1019 genes elevated in psoriasis lesions and their expression across 10 cell types. We identified 1019 PP-increased
DEGs with PP/PN fold-change greater than 1.50 and FDR less than 0.05 (n = 216 patients; Wilcoxon rank sum test). These genes were clustered based
upon their expression pattern across 10 cell types (Spearman correlation distance and average linkage). The red-blue heatmap shows expression of
genes in each cell type, with red colors indicating relatively high expression (compared to normal human skin) and blue colors indicating relatively
low expression (compared to normal human skin). The yellow-black heatmap shows the cell type assigned to each gene (i.e., the cell type for which
the gene’s median expression was highest, with detection frequency greater than 10%). The chart on the far right shows the estimated median
fold-change (PP/PN) for each gene (n = 216 patients).
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a trend towards elevated expression in some patients,
but not others (Additional file 9). Genes specifically
expressed by KCs, in contrast, showed a significant trend
towards PP-increased expression in nearly all patients
(86%) (Additional file 9).
Psoriasis-decreased DEGs are enriched with genes
expressed at high levels in fibroblasts and reticular
dermis
PP-decreased DEGs included a disproportionate number
of genes assigned to fibroblasts (P < 0.05; Fisher’s Exact
Test; Figures 2 and 4). This trend was reinforced by a
rank-based analysis, which showed that fibroblast-
associated genes tended to have decreased expression in
PP versus PN skin (P = 1.2 × 10−97; GSEA; Additional
file 6, Part B). Additionally, whereas PP-decreased DEGs
usually had lower-than-expected detection frequency
and expression in most cell types, this wasn’t the case
for fibroblasts; in contrast, PP-decreased DEGs had
higher-than-expected detection frequency in fibroblasts
on average (P = 0.048; Additional file 10). Moreover, fornearly all patients (84%), fibroblast signature scores were
significantly low (P < 0.05), indicating that genes specific-
ally expressed by fibroblasts tend to decline in PP skin
(Additional file 9). Consistent with these results, PP-
decreased genes were enriched with respect to genes
showing elevated expression in LCM-dissected reticular
dermis in comparison to normal human skin (P = 1.2 ×
10−46; GSEA; data not shown). 33% of PP-decreased
DEGs (291/885) were expressed more highly in fibro-
blasts than any other cell type (Figure 2), of which
TSPAN8 and PAMR1 were among the most strongly
repressed in psoriasis lesions (Additional file 11). PP-
decreased DEGs assigned to fibroblasts were associated
with functions involving development, morphogenesis
and cell adhesion (data not shown).
Psoriasis and innate immunity: candidate genes from
psoriasis GWAS studies are enriched for genes expressed
at high levels in neutrophils
Genome-wide association studies (GWAS) of psoriasis
have been instrumental in identifying genes likely to
be involved in the psoriasis disease process [1,2]. We
Figure 4 Cluster analysis of 885 genes decreased in psoriasis lesions and their expression across 10 cell types. We identified 885 PP-decreased
DEGs with PP/PN fold-change less than 0.67 and FDR less than 0.05 (n = 216 patients; Wilcoxon rank sum test). These genes were clustered based upon
their expression pattern across 10 cell types (Spearman correlation distance metric and average linkage). The red-blue heatmap shows the expression
of each gene in each cell type, with red colors indicating relatively high expression (compared to normal human skin) and blue colors indicating
relatively low expression (compared to normal human skin). The yellow-black heatmap shows the cell type assigned to each gene (highest median
expression with detection frequency greater than 10%). The chart on the far right shows the estimated median fold-change (PP/PN) for each gene
(n = 216 patients).
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bility loci, including those listed in the NHGRI GWAS
catalogue and those identified in a recent psoriasis meta-
analysis (see Methods) [26]. Most GWAS candidates
were assigned to immune cell types, with a dispro-
portionately large number assigned to neutrophils and
macrophages (neutrophils, P = 1.5 × 10−5; macrophages,
P = 0.012; Fisher’s Exact Test; Figure 2). Consistent with
these trends, the candidate genes, on average, had higher-
than-expected detection frequency and expression in all
immune cell types (P ≤ 0.059), but this was not the case
with respect to KCs and fibroblasts (Additional file 12).
GWAS candidates assigned to neutrophils were associated
with diverse immune functions, such as cytokine produc-
tion, response to other organism, and innate immune re-
sponse (data not shown).
We also analyzed a set of 357 psoriasis-associated
genes from the Human Genome Epidemiology Network
(HuGENet) database [33]. This set includes candidate
genes from psoriasis GWAS studies, but in addition in-
cludes genes identified from non-GWAS epidemiologicpopulation-based studies [33]. In agreement with the
above analyses, the 357 HuGENet genes were enriched
with neutrophil-assigned genes (Additional file 13). We
next combined the 117 GWAS candidates with the 357
HuGENet genes, yielding a maximally comprehensive set
of 439 genes associated with psoriasis based upon genetic
analyses (Additional files 13 and 14). This set of genes was
also significantly enriched with neutrophil-assigned genes,
with approximately 19% of genes (82/439) expressed more
highly in neutrophils than any other cell type (Additional
files 13 and 14).
Further inspection of the 117 psoriasis GWAS candi-
dates revealed that, for many, expression was significantly
altered in psoriasis lesions, although in most cases esti-
mated fold-changes did not meet DEG criteria (Figure 5).
Overall, 13 candidate genes were also PP-increased DEGs,
while 2 others were PP-decreased DEGs (Figure 5). Candi-
date genes varied in the degree to which expression was
specific to a given cell type, and this influenced the confi-
dence with which candidate cell types could be assigned
(Figure 6). With respect to LCE3D, for instance, KCs were
Figure 5 Top 30 GWAS candidates with altered expression in psoriasis lesions and their expression across 10 cell types. The table lists
the 30 psoriasis GWAS candidates for which expression was most strongly altered in psoriasis lesions (i.e., lowest p-value, Wilcoxon rank sum test;
n = 216 patients). Each of the listed genes was skin-expressed, with expression detected above background with respect to at least 10% of the
432 PP and PN skin samples from all 216 patients. The color scale denotes median expression of each gene, as compared to the gene’s median
expression in normal human skin. Red colors thus denote expression that is higher in comparison to normal human skin, while blue colors
indicate that expression is lower in comparison to normal human skin. For each gene and cell type, black circles indicate the percentage of
microarray samples for which the gene’s expression was detected above background (P < 0.05, Wilcoxon signed-rank test). Red labels (left margin)
denote PP-increased DEGs (FDR < 0.05 with median PP/PN fold-change > 1.5), while blue labels (left margin) represent PP-decreased DEGs
(FDR < 0.05 with median PP/PN fold-change < 0.67). The cell type assigned to each gene is listed in the right margin. Magenta labels denote cases
in which the gene’s expression in the assigned cell type is significantly higher than its expression in any of the other 9 cell types (FDR < 0.05,
Wilcoxon rank sum test).
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since expression was distinguishably greater in KCs as
compared to any other cell type (Figures 5 and 6). Among
the candidate genes for which cell type assignment con-
fidence was greatest, most were assigned to KCs or neu-
trophils, although some were also assigned to fibroblasts
(e.g., PTRF and FNDC1; see Figure 6).Susceptibility-associated variation at rs11121129 disrupts
an AP1 binding site associated with TNFRSF9 expression
in neutrophils
The assignment of cell types to candidate genes provides a
first step towards an improved functional understanding
of susceptibility variants. To illustrate this point, we here
develop a procedure for analysis of intergenic risk loci,
Figure 6 Cell type assignments for 105 psoriasis GWAS candidate genes. The left margin lists each individual gene, the assigned cell type, and
the gene’s detection frequency with respect to that cell type (KC = keratinocytes; FB = fibroblasts; CD4 = CD4+ T-cells; NK = NK Cells; CD8 = CD8+ T-cells;
B = B-cells; MP =macrophage; MC =monocyte; DC = dendritic cells; NP = neutrophils). Genes are ranked by the degree to which they showed specific
expression in the assigned cell type. To obtain the p-value shown for each gene, expression in the assigned cell type was compared to expression in
each of the other nine cell types, respectively (n= 50 samples per cell type; Wilcoxon rank sum test). The p-value shown for each gene corresponds to
the largest p-value obtained from each of the 9 comparisons to other cell types (asterisk, FDR < 0.05).
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date gene transcription and allele-specific transcription
factor binding [39-41]. The procedure requires identifica-
tion of a candidate cell type for a suspected target gene
near a susceptibility locus. Transcription factors (TFs) that
potentially regulate the target gene are then identified
based upon co-expression analysis. Finally, we identify
SNPs at which variation is predicted to influence binding
of these TFs. The overall strategy is illustrated below using
the TNFRSF9 risk locus as an example (i.e., rs11121129).
Individuals carrying the A allele at rs11121129 (chr1,
8268095) have elevated psoriasis risk (OR = 1.13; P = 1.7 ×
10−8), but mechanisms underlying this association are not
known, since the locus is non-coding and does not affect
protein structure [26]. Candidate genes near this locus in-
clude solute carrier family 45 member 1 (SLC45A1) and
tumor necrosis factor receptor superfamily member 9(TNFRSF9). Expression of SLC45A1 (distance from SNP:
116.3 kb) was rarely detectable in any of the 10 cell types
we considered (data not shown). On the other hand,
expression of TNFRSF9 (distance: 264.9 kb) was fre-
quently detected in immune cells and was almost always
detected in neutrophils (>99%), which was the cell type
for which TNFRSF9 expression was quantitatively highest
(Figure 7A). Consistent with this, we used RT-PCR and
flow cytometry to show that TNFRSF9 mRNA and protein
expression was highest in neutrophils, as compared
to other cell types, including T-cells and monocytes
(Additional file 15). Moreover, in agreement with mi-
croarray data (Figure 5), RT-PCR confirmed significant
elevation of TNFRSF9 expression in psoriasis lesions as
compared to uninvolved and normal skin (Additional
file 15). We thus hypothesized that genetic variation
at rs11121129 (or linked SNPs) altered the affinity of
Figure 7 Identification of 91 genes co-expressed with TNFSRF9 in neutrophils. (A) Expression of TNFSRF9 across 10 cell types. Expression is
normalized to that observed in normal human skin. Values in yellow denote TNFSRF9 detection frequency. (B) Procedure used to identify TNFSRF9-co-
expressed genes in neutrophils. For genes expressed in both skin and neutrophils, we calculated the Spearman correlation coefficient between the
expression pattern of each gene and that of TNFSRF9 (n = 426 neutrophil microarray samples). Genes were ranked based upon the estimated
Spearman correlation coefficient (raised to the 7th power). To identify an appropriate cut-off for TNFSRF9-co-expressed genes, we located the “bend” in
the curve of descending correlation coefficient estimates (i.e., the rank minimizing the length of the red line). (C) The gene most strongly associated
with TNFSRF9 expression in neutrophils was VAV1. The scatterplot compares normalized expression values (log2 scale) between TNFSRF9 and VAV1 in
neutrophils. (D) Expression of 91 genes co-expressed with TNFRSF9 in neutrophils (n = 426 microarray samples). Microarray samples were ordered with
TNFRSF9 expression descending from left to right. Gold regions outline the middle 50% of normalized expression values among the 91 genes. Blue
regions outline the middle 80% of normalized expression values among the 91 genes. Expression of each gene was normalized to its baseline
(average) expression across all 426 samples, such that positive values correspond to above-average expression and negative values correspond to
below-average expression.
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TNFRSF9 expression in neutrophils.
We assembled a dictionary of 1937 empirically-deter-
mined DNA motifs recognized by human TFs and other
DNA-binding proteins (see Methods). We then assessed
whether any of these motifs were enriched with respect to
intergenic sequences adjacent to TNFRSF9 and those
genes co-expressed with TNFRSF9 in neutrophils. We
identified 91 genes co-expressed with TNFRSF9 in neutro-
phils, based upon a rank analysis of Spearman correlationcoefficients (Figure 7B and D). The gene most strongly
correlated with TNFRSF9 expression, for instance, was vav
1 guanine nucleotide exchange factor (VAV1) (rs = 0.64;
Figure 7C). We next identified 595 motifs that occurred at
significantly elevated frequency among intergenic regions
adjacent to TNFRSF9 and its co-expression partners in
neutrophils (FDR < 0.05 with Z > 0). We reasoned that
binding of such motifs may be disrupted by susceptibility-
associated variation near rs11121129. We identified five
SNPs linked with rs11121129 (r2 > 0.90), yielding a total of
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which these SNPs altered sequences matching those
motifs enriched with respect to genes co-expressed with
TNFRSF9 in neutrophils (Figure 8A).
The risk allele at rs6687168 (265.7 kb upstream
of TNFRSF9) abrogated a c-Fos (AP-1) binding site
(Figure 8B, D and E) that was enriched among inter-
genic sequences adjacent to TNFRSF9-co-expressed genesFigure 8 Susceptibility-associated variation at rs11121129 disrupts an A
(A) Top 10 binding sites ranked according to their enrichment with respect t
The listed binding sites include only those that are sensitive to variation at SN
the Z statistic quantifying the degree to which each binding site is enriched a
p-values are listed in the left margin, where an asterisk symbol is used to den
predicted to influence binding. Blue font denotes binding sites for which the
binding sites for which the risk variant engenders a match to the binding site
position for which variation at rs6687168 is predicted to influence binding (se
black arrow denotes the position for which variation at rs6661746 is predicted
variant at rs6687168 (Chr 1, 8268893 – 8268933). (E) Top 10 binding sites mat
(D) and (E), the right margin lists p-values quantifying the degree to which m
genes in neutrophils.(P = 3.4 × 10−15; Figure 8A). Notably, a risk allele at
rs6661746 (265.4 kb upstream of TNFRSF9) also abrogated
an NF-κB binding site enriched among intergenic se-
quences adjacent to TNFRSF9-co-expressed genes, al-
though the degree of enrichment was weaker (P = 7.8 ×
10−9; Figure 8A). These results suggest the hypothesis
that AP-1 binds the C allele at rs6687168, leading to a
psoriasis-protective effect via the effect of this interactionP1 binding site associated with TNFRSF9 expression in neutrophils.
o sequences adjacent to genes co-expressed with TNFRSF9 in neutrophils.
Ps in linkage disequilibrium with rs11121129 (r2 > 0.90). The chart shows
mong sequences adjacent to TNFRSF9-co-expressed genes. Associated
ote FDR < 0.05. The right margin lists the SNP for which variation is
risk variant abrogates a match to the binding site, while red font denotes
. (B) Sequence logo for Fos|SWGNSNSMDG. The black arrow denotes the
e parts D and E). (C) Sequence logo for CREL|BGGNNTTTCC|M00053. The
to influence binding. (D) Top 10 binding sites matching the non-risk
ching the risk variant at rs6687168 (Chr 1, 8268893 – 8268933). In both
otifs are enriched among sequences adjacent to TNFRSF9-co-expressed
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does not bind the T allele at rs6687168, leading to in-
creased psoriasis risk.
Susceptibility-associated variation alters binding sites
(AP-1, IRF1, STAT3 and STAT4) enriched in sequences
near candidate genes and their co-expression partners
We repeated the analysis described above but focused on
other intergenic loci identified from a recent GWAS meta-
analysis of psoriasis (Additional file 16) [26]. Our analysis
included a chromosome 9 SNP (rs10979182) within a “gene
desert”, 565 kb upstream of KLF4, which encodes a TF
known to control KC differentiation. Consistent with this,
KLF4 was most strongly expressed in KCs as compared
to other cell types (Additional file 16, Part E). With respect
to KCs, we identified an AP-1 motif enriched with respect
to sequences near genes co-expressed with KLF4 (P = 2.3 ×
10−3), and found that a linked psoriasis risk variant at
rs7850481 (543 kb upstream of KLF4) abrogated a match
to this motif (Additional file 16, Part E). On the other hand,
the risk variant 72 kb upstream of IL12B (rs12188300)
engendered a motif recognized by AP-1, which was asso-
ciated with IL12B-co-expressed genes in dendritic cells
(Additional file 16, Part C). These results, taken together,
suggest that AP-1:DNA interactions are sensitive to suscep-
tibility-associated genetic variation, potentially impacting ex-
pression of candidate genes in both KCs and immune cells.
B3GNT2 encodes a type II transmembrane enzyme
located 99.6 kb from an intergenic susceptibility locus on
chromosome 2 (rs10865331). Expression of B3GNT2 is ubi-
quitous with detection frequency greater than 99% for each
of the 10 cell types we considered; however, expression was
quantitatively higher in macrophages as compared to other
cell types (Additional file 16, Part B). Genes co-expressed
with B3GNT2 in macrophages were located next to inter-
genic sequences with elevated density of motifs recognized
by TFs important to psoriasis pathogenesis, such as IRF1,
STAT4 and STAT5 (Additional file 16, Part B). With re-
spect to the IRF1 motif, a putative binding site is sensitive
to variation at rs6759003 (107 kb from the B3GNT2 tran-
scription stop site), with the risk allele predicted to increase
IRF1 affinity (Additional file 16, Part B). Similarly, we iden-
tified a second locus at rs13024541 (104 kb from B3GNT2)
for which the risk variant increased affinity for STAT TFs
enriched in sequences near B3GNT2-co-expressed genes in
macrophages, including STAT4, STAT5A and STAT6
(Additional file 16, Part B). These results are consistent
with the hypothesis that susceptibility-associated variation
near B3GNT2 leads to increased IRF1 and STAT1 binding
to modify B3GNT2 expression in macrophages.
Discussion
Genome-scale studies of psoriasis have identified many
genes involved in the disease process, but further work isneeded to understand how each gene contributes to lesion
development. The main goal of this study, therefore, was
to extend findings from expression profiling and GWAS
studies of psoriasis by establishing connections between
individual genes and candidate cell types. We estimate
that 50% of genes differentially expressed in psoriasis le-
sions (DEGs) can be attributed to KCs or fibroblasts, with
the other 50% driven by the activities of immune cells.
This contrasted with genes implicated in psoriasis GWAS
studies, which were less frequently assigned to KCs or
fibroblasts (20%), but were more commonly assigned to
immune cells (71%) with many showing highest expres-
sion in neutrophils (24%). This latter result emphasizes
the role of the innate immune system in psoriasis, con-
sistent with novel loci uncovered in a recent psoriasis
GWAS meta-analysis [26]. The identification of candidate
cell types provides an important first step towards func-
tional analysis, and to illustrate this idea we developed a
systematic approach for generating hypotheses to explain
GWAS hits at intergenic loci. This allowed us to identify
(non-coding) susceptibility-associated variation predicted
to influence binding of TFs associated with co-expression
networks in specific cell types. Our findings suggest new
mechanisms by which non-coding susceptibility alleles
might regulate expression of nearby target genes, inclu-
ding mechanisms mediated by the binding of sequence-
specific factors such as AP-1, NF-κB, IRF1, STAT3 and
STAT4.
It has often been assumed that differential expression
trends in psoriasis lesions are driven mostly by KCs,
which are the majority cell type in full-thickness skin
biopsies. This expectation is more likely correct for
genes with significantly elevated expression in psoriasis
lesions, but is less likely correct for genes with decreased
expression. Among DEGs with decreased expression in
lesions, we assigned twice as many to fibroblasts (33%)
as to KCs (15%) (Figure 2). This result is consistent with
previous findings [3,6,42] and may be attributed to se-
veral mechanisms. First, angiogenesis within psoriasis le-
sions expands the dermal vasculature [43], and this may
decrease the number of fibroblasts and consequently the
abundance of fibroblast-derived mRNAs. Second, it is
possible that epidermal expansion in psoriasis lesions
leads to increased expression of KC-derived transcripts
and that this effectively dilutes transcripts derived from
minority cell types, such as fibroblasts [42]. It is notable
that neither of these possibilities requires any shift in
transcription on a per-cell basis in fibroblasts. Neverthe-
less, changes in the transcriptional activity of fibroblasts
do occur and are likely to shape the transcriptome of
full-thickness lesional skin biopsies to some degree.
Psoriatic fibroblasts, for example, produce excessive
amounts of cytokines such as IL-6 and IL-8 [44,45], and
it has been proposed that these and other fibroblast-
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KC proliferation and differentiation [46]. Further work will
thus be needed to better understand why fibroblast-
derived mRNAs are so abundant among psoriasis-de-
creased DEGs, and in this regard, we expect that analyses
of dermal and epidermal sections of lesions obtained by
laser capture microdissection will prove informative [47].
Understanding the contribution of fibroblasts to the pso-
riasis transcriptome will likely have implications for the
interpretation of genome-wide expression patterns in
other skin diseases as well, since we observed strong over-
lap between psoriasis DEGs and those genes with altered
expression in other skin diseases, such as squamous cell
carcinoma, atopic dermatitis and Mediterranean spotted
fever eschars (Figure 1 and Additional file 4).
Development of an inflammatory infiltrate is a charac-
teristic feature of psoriasis lesions, although even macro-
scopically normal skin includes a sizable immune cell
population [48]. Psoriasis-increased DEGs included a
slightly higher-than-expected number of genes assigned to
macrophages (Figure 2) and the most strongly elevated
DEGs (>2-fold) included a significant proportion of genes
most highly expressed by neutrophils (data not shown).
We could also identify some psoriasis-decreased DEGs
expressed mostly by immune cells (Figure 4), possibly
representing cases in which the altered environment of
psoriasis lesions led to down-regulation of transcription
within resident (non-infiltrating) immune cells. Overall,
the proportion of psoriasis DEGs associated with T-cells,
NK-cells, B-cells, DCs and monocytes was limited
(Figure 2). This is most likely due to the variable degree of
inflammatory cell infiltration that occurs among lesions,
which may be associated with variation among lesions
with respect to developmental stage, genetic background,
or environmental factors (Additional file 9) [3,6,49]. As a
result of this variation, genes associated with infiltration
by these cell types may be excluded from DEGs, which in-
stead include genes showing consistent responses across
lesions (e.g., KCs and fibroblasts). This suggests that, in
order to study inflammatory cell infiltration in psoriasis le-
sions, large sample sizes are generally needed, and a strict
focus on genes meeting criteria for differential expression
is insufficient [3,6]. It is interesting to note that the most
consistent inflammatory signature was observed for neu-
trophils (Additional file 9). Among lesions from the 216
patients, we almost always observed a slight increase in
the expression of neutrophil signature genes; moreover, in
contrast to other immune cell types, we never observed
patients showing a significant decrease in the expression
of neutrophil signature genes (Additional file 9).
Neutrophils are a hallmark feature of psoriasis lesions
and are located in concentrated areas under the stratum
corneum where they form regions known as Munro’s
microabscesses [24]. In our analysis, there was significantenrichment of neutrophil-assigned genes among GWAS
candidates, with 1 of every 4 candidates expressed more
highly in neutrophils than any other cell type (Figure 2).
Whether neutrophils have a causative role in the deve-
lopment of psoriasis lesions remains unclear, but their
appearance in lesions precedes that of T-cells [49], and re-
gions near neutrophil microabscesses show heightened
mitosis and epidermal growth [24,50]. Prior studies have
also demonstrated a correlation between lesion develop-
ment and abundance of neutrophils in circulation [51,52],
and reduction of peripheral neutrophils using adsorption
apheresis was reported to improve psoriasis lesions in 39
of 44 patients [53]. Neutrophils also represent a source of
cytokines demonstrated to drive lesion development, such
as IL-17A, and indeed one study indicated that IL-17A(+)
neutrophils are more abundant in lesions than IL-17A(+)
T-cells [54]. Such epidermal neutrophils generate reactive
oxygen species such as superoxide anion, leading to tissue
damage and possible hyper-activation of innate defense
mechanisms [55]. Neutrophils also interact with other cell
types, such as KCs, T-cells and dendritic cells. For ex-
ample, KCs can be induced to express cell surface mole-
cules, such as the adhesion glycoprotein CEACAM1,
which facilitate KC-neutrophil interactions and prolong
lifespan of neutrophils once removed from circulation
[56]. Under certain conditions, moreover, neutrophils ex-
press MHC class II molecules such as HLA-DR, which
may allow neutrophils to interact directly with T-cells and
participate in antigen presentation and T-cell activation
[24,57-59]. Post-apoptotic neutrophils within the epider-
mis may also provide a source of autoantigens by the for-
mation of neutrophil extracellular traps (NETs) consisting
of a web-like chromatin structure, human neutrophil elas-
tase (HNE), cathelicidin (LL37), and secretory leukocyte
proteinase inhibitor (SLPI) [60-62]. These NET compo-
nents provide DNA complexes that can enhance pDC
activation and production of cytokines such as IFN-α [60].
Genome-scale studies of psoriasis are exploratory and
not hypothesis-driven, but such studies can provide the
leads necessary to begin hypothesis-driven investigations
into pathogenetic mechanisms [1,2]. We and others have
emphasized that identification of candidate cell types is
necessary as a first step towards functional analysis of in-
dividual genes [7]. Along these lines, one starting point
may be the limited set of 15 genes implicated from GWAS
results that are also included among DEGs with altered
expression in psoriasis lesions (Figure 5). Of these 15
DEGs, two attractive candidates are LCE3D and GRHL3,
since both genes show a trend towards cell type-specific
expression, with strong expression in KCs but lacking
detectable expression in other cell types (Figure 5). Con-
sistent with KC-specific expression, LCE3D encodes a
cornified envelope protein [63] and GRHL3 encodes a
TF that activates a pro-differentiation gene expression
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psoriasis susceptibility loci, most are expressed by multiple
cell types (Figure 5). Of these, however, 5 were expressed
more highly in neutrophils than any other cell type (IFIH1,
PPIF, IL12B, DDX58 and STAT3). Interestingly, IFIH1
(also known as MDA5) and DDX58 (also known as RIG-I)
encode (RIG-I-like) receptors that recognize virus-derived
intracellular DNA and thus serve as a part of the cytosolic
trigger for activation of innate immune responses [64]. Re-
cently, this viral response pathway emerged from a large-
scale analysis of expression data, where it was designated
as the “STAT1-57” regulon and shown to be activated in
psoriasis lesions, cytokine-inducible (e.g., IFN-γ, IFN-α,
TNF, IL-1α), and repressed in vivo by biologic therapies or
glucocorticoids [65]. IFIH1 and DDX58 are expressed in
human KCs where they function as RIG-I-like receptors
to initiate antiviral defenses [66,67]. These receptors, how-
ever, have similar functionality in neutrophils, suggesting
that this same antiviral pathway might be activated in
multiple cell types from the psoriatic epidermis [68].
The majority of signals identified in psoriasis GWAS
studies are located in non-coding regions and this has
also been the case for other complex genetic diseases
[26,32,69,70]. Susceptibility-associated variation at non-
coding loci may influence gene expression by altering
TF binding, but it is time-consuming to test hypotheses
regarding the effects of individual SNPs on TF binding
and downstream expression [39-41]. We therefore devel-
oped an approach to prioritize candidate regulatory me-
chanisms, which provides a rank-ordering of potentially
causal non-coding SNPs at which susceptibility-asso-
ciated variation is predicted to influence TF binding in
specific cell types. We applied this strategy to six inter-
genic susceptibility loci identified from a recent psoriasis
GWAS meta-analysis (Additional file 16) [26]. We iden-
tified SNPs near TNFRSF9 at which psoriasis susceptibi-
lity variants disrupted binding sites for AP-1 (rs6687168)
and NF-κB (rs6661746), where both binding sites
were also enriched with respect to sequences adjacent
to genes co-expressed with TNFRSF9 in neutrophils
(Figures 7 and 8). In T-cells, a prior study has confirmed
that AP-1 and NF-κB positively regulate TNFRSF9 ex-
pression [71,72], although it is unclear whether such
regulation occurs in neutrophils or other immune cell
types. TNFRSF9 (also CD137 or 4-1BB) encodes a TNF
receptor superfamily membrane protein that mediates
T-cell activation [73], but TNFRSF9 is also expressed by
other immune cells including neutrophils [74]. Within
psoriasis lesions, TNFRS9 expression on neutrophils may
have pro- and anti-inflammatory effects. On the one
hand, expression of TNFRS9 inhibits extension of neu-
trophil lifespan mediated by the anti-apoptotic effects of
cytokines such as IFN-γ, and this can increase neutrophil
apoptosis and reduce cytotoxic damage associated withneutrophil infiltration [75,76]. These same effects, how-
ever, may favor the formation of NETs, providing a
source of autoantigens and contributing to pDC activa-
tion [60]. Loss of TNFRSF9 expression due to psoriasis
susceptibility alleles may thus have either pro- or anti-
inflammatory effects by altering the balance of forces
affecting neutrophil apoptosis.
Psoriasis is now understood to be an (auto)-immune
disease that is dependent upon interactions between KCs
and immune cells [2,9,13]. The exact cell type underlying
the primary defect leading to development of psoriasis le-
sions has been extensively debated, and at a glance, fin-
dings from psoriasis GWAS studies have been mixed,
with some loci seeming to support a primary role for KCs
and others pointing towards innate or adaptive immune
cells [9,11,14]. The analysis of gene expression alone is not
sufficient to resolve this issue, but quantitative analyses of
gene expression can at least provide objective insights [7].
Our analysis of genes near susceptibility loci from psoria-
sis GWAS studies lends support to multiple cell types, in-
cluding T-cells, but above all our findings bolster support
for neutrophils as participants in pathogenetic disease
mechanisms [24,49,54,55,60]. We expect that this conclu-
sion can be sharpened by future work, based upon the
identification of new psoriasis susceptibility loci, new
experimental evidence, generation of new datasets for
evaluating cell type-specific expression, and continued de-
velopment of bioinformatic analysis protocols. This on-
going work will contribute to the broader goal of finding
connections between individual genes and their disease-
relevant cell types [7]. This gene-cell mapping will, in turn,
be essential for the design of hypothesis-driven functional
studies, which will be needed to fully integrate findings
from GWAS studies into our understanding of psoriasis
disease mechanisms.
Conclusions
The purpose of this study was to extend findings from ex-
pression profiling and GWAS studies by mapping identi-
fied genes to candidate cell types. Our findings indicate
that approximately 50% of psoriasis DEGs can be attrib-
uted to resident skin cells, although the dominant cell type
differs between psoriasis-increased DEGs (keratinocytes,
35%) and psoriasis-decreased DEGs (fibroblasts, 33%). In
contrast, genes located near susceptibility loci from pso-
riasis GWAS studies are predominantly associated with
immune cells (71%), and for such genes there is a signifi-
cant tendency for expression to be highest in neutrophils
(24%, P = 1.5 × 10−5). We have also investigated GWAS
hits at (non-coding) intergenic psoriasis susceptibility loci
to identify sites at which allele-specific TF binding may in-
fluence candidate gene expression. Our results suggest
new hypotheses for interpretation of intergenic hits from
psoriasis GWAS studies, and we have identified SNPs
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STAT3 and STAT4. Taken together, our findings offer ob-
jective and data-driven evidence supporting the idea that
innate immunity and neutrophils contribute to psoriasis
pathogenesis. Additionally, by mapping genes to cell types,
we have taken steps towards post-GWAS functional ana-
lysis of psoriasis susceptibility loci, and for the first time
we have implemented a strategy for interpretation of
GWAS hits within intergenic (non-coding) regions.
Methods
Ethics statement
Skin biopsies were obtained from volunteer patients in ac-
cordance with Declaration of Helsinki principles [6,27-31].
Informed written consent was provided by each partici-
pant under protocols approved by an independent ethics
committee or institutional review board (Alfred Hospital,
Melbourne, Australia; Chesapeake Research Review Inc.,
Columbia, MD; Research Review Board Inc., Richmond
Hill, Ontario, Canada; Rockefeller University, New York,
NY, IRB no. AMA-0674; Royal Adelaide Hospital, Adelaide,
Australia; University of Michigan, Ann Arbor, MI, IRB No.
HUM00037994).
Microarray analysis of psoriasis gene expression data
Data were pooled from 8 studies that had used microar-
rays to evaluate gene expression in lesional and unin-
volved skin from psoriasis patients (Additional file 17;
Gene Expression Omnibus accession IDs: GSE13355,
GSE14905, GSE30999, GSE34248, GSE41662, GSE41663,
GSE47751 and GSE50790) [6,27-31]. The same commer-
cial oligonucleotide microarray platform was used in each
study (Affymetrix Human Genome U133 Plus 2.0 array).
The initial dataset included 458 paired PP and PN samples
from 229 patients. CEL data files were evaluated using
Affymetrix quality control (QC) metrics, such as average
background, scale intensity factor, RNA degradation score,
percentage of probe sets called present, and four metrics de-
rived from probe level models (NUSE median, NUSE IQR,
RLE median, RLE IQR) (Additional file 18, Parts A – H)
[77]. A sample was removed if it was extreme with respect
to the complete dataset or other samples from the same
study (since data from each study was normalized inde-
pendently, see below). This ensured that all samples
normalized together could be compared under viable
normalization assumptions. After QC filtering, there
remained 434 paired PP and PN samples from 217
patients.
Post-QC samples were normalized using Robust Multi-
chip Average (RMA). Samples from GSE14905, GSE34248,
GSE41662, GSE41663, GSE47751 and GSE50790 were each
normalized independently using RMA. For GSE13355,
samples had been processed in three batches over three
consecutive years, but PP and PN samples from the samepatient were always allocated to the same batch. The three
batches of samples were therefore normalized (by RMA)
independently of one another. Similarly, for GSE30999,
samples had been collected at 10 study sites, with PP and
PN samples from the same patient always collected at the
same site. GSE30999 samples were thus normalized in 10
different batches, with each batch including only samples
from the same study site. Given these normalization pro-
cedures, samples from each dataset and/or batch were
normalized separately, but in every case PP and PN sam-
ples from the same patient were normalized together.
After normalization, PP versus PN differences in RMA ex-
pression scores were calculated for each probe set and
each patient, and these differences were pooled across all
batches and all studies.
Affymetrix arrays feature multiple “sibling” probe sets
designed to target the same gene [78]. To limit redun-
dancy, we a priori chose a single probe set to evaluate for
each of the 20184 human genes represented on the Affy-
metrix Human Genome U133 Plus 2.0 array. In choosing
the representative, we preferentially selected probe sets
expected to hybridize specifically with its target, excluding
those probe sets containing either an “_s_” or “_x_” suffix
in the Affymetrix probe set identification number [79]. If
there was more than one probe set representing the same
gene, but no difference in expected hybridization specifi-
city, the representative probe set was chosen as the one
for which median RMA expression was the highest across
all 434 PP and PN samples. For each probe set, we cal-
culated the median RMA expression score among PP
samples, the median RMA expression score among PN
samples, averaged these two values, and chose as a repre-
sentative the probe set for which this average value was
greatest. For 15175 genes (75.2%), the chosen representa-
tive probe set was expected to hybridize specifically with a
single mRNA transcript from the target gene. For nearly
all other genes (21.8%), the representative was expected to
hybridize non-specifically but only with mRNAs derived
from the same human gene (i.e., probe sets with an “_s_”
suffix) [79].
We next inspected samples to assess whether genes
characteristically increased or decreased in psoriasis le-
sions showed expected trends (Additional file 18, Part I).
This revealed one outlier patient for which genes typically
increased in PP skin were decreased, while conversely,
genes typically decreased in PP skin were increased
(GSE30999; samples GSM768097 and GSM768096). Most
likely, for this patient, PP and PN labels had been reversed
during sample processing in the laboratory. Nevertheless,
since it was not possible to confirm the labeling error,
samples from this patient were excluded. Following these
pre-processing steps, there remained 432 paired PP and
PN samples from 216 patients, with samples from all pa-
tients showing expected trends for genes characteristically
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I). Finally, the 216 patients were clustered based upon PP
versus PN differences in RMA expression scores across
16358 skin-expressed genes (Additional file 18, Part J).
Cluster analysis did not identify strong outliers and further
showed that patients did not cluster primarily according
to the dataset from which patient samples were derived
(Additional file 18, Part J). Consistent with prior work
[30], this indicated that variation among the 216 patients
is only weakly associated with study-specific factors.
Differential expression analyses were carried out with
respect to 16358 skin-expressed genes. We here consider
skin-expressed genes to be those for which expression
was detected for at least 10% of the 432 biopsies (PP and
PN) from the 216 patients. Detection of representative
probe sets was assessed by testing for a difference in
signal intensities between paired perfect match (PM)
and mismatch (MM) probes, with a significant difference
providing evidence for detection of a probe set above
background (P < 0.05; one-sided Wilcoxon signed-rank
test) [38]. For the 16358 skin-expressed genes, a non-
parametric method was used to assess differential ex-
pression between paired PP and PN biopsies (Wilcoxon
rank sum test; n = 216 patients). To control the false dis-
covery rate (FDR), raw p-values were adjusted using the
Benjamini-Hochberg correction [80]. For identification
of differentially expressed genes (DEGs), we required
FDR < 0.05 along with median PP/PN fold-change (FC)
greater than 1.50 or less than 0.67. In addition, PP-
increased DEGs included only those genes for which
median FC was greater than 1 with respect to each of
the 8 studies included in our analysis. Similarly, PP-
decreased DEGs included only genes for which median
FC was less than 1 with respect to each of the 8 studies.
This ensured that DEGs showed consistent trends across
all studies included in the analysis. These criteria yielded
1019 PP-increased DEGs (FC > 1.50 and FDR < 0.05)
along with 885 PP-decreased DEGs (FC < 0.67 and
FDR < 0.05).
Gene expression across 10 cell types (keratinocytes,
fibroblasts, CD4+ T-cell, NK cell, CD8+ T-cell, B-cell,
macrophages, monocytes, dendritic cells, neutrophils)
We used microarray data from Gene Expression Omnibus
to construct a database for evaluation of gene detec-
tion and expression across 10 disease-relevant cell types
(Additional file 5). Data samples were generated from the
same microarray platform used to profile expression in
lesional and uninvolved skin from psoriasis patients
(Affymetrix Human Genome U133 Plus 2.0 array). For
each cell type, an initial batch of CEL files was down-
loaded and screened to filter out low-quality hybri-
dizations. We removed 5% of samples with extreme
background (2.5% lowest and 2.5% highest), 5% of sampleswith extreme scale parameters (2.5% lowest and 2.5%
highest), 5% of samples with the fewest probe sets called
present, and 5% of samples with high RNA degradation
scores (Additional file 5). Based on these QC criteria, we
excluded 11 – 15% of CEL files initially identified for each
cell type (Additional file 5). A representative probe set was
evaluated for each human gene represented on the array,
and for consistency, we used the same representatives as
in our analysis of differential expression in PP and PN skin
(see above). Similarly, as above, a gene was considered de-
tected in a sample if there was a significant difference in
signal intensities between PM and MM probes (one-sided
Wilcoxon signed-rank test) [38]. A gene’s overall detection
frequency for a cell type was thus calculated as the pro-
portion of post-QC samples for which this test was signifi-
cant (P < 0.05).
Relative expression across cell types was evaluated
based upon 50 representative microarray samples chosen
for each cell type. To identify these samples, all post-QC
samples for a given cell type were normalized by RMA
and we calculated a centroid by averaging expression for
each gene across samples. The 50 representative samples
were then chosen by identifying those for which the
Euclidean distance between the sample and cell type
centroid was minimal. After the 50 representative sam-
ples had been identified for each cell type, representa-
tives from all cell types were normalized together by
RMA to create a composite dataset. For normalization
purposes, the composite dataset also included 50 repre-
sentative microarray samples used to evaluate expression
in normal human skin (i.e., representatives chosen from
131 post-QC normal skin samples). In total, therefore,
the composite dataset consisted of 550 microarray sam-
ples, including representatives from 10 cell types in
addition to normal human skin. These data were used to
compare relative expression across cell types, with ex-
pression values for each gene normalized to its median
expression in normal human skin.
Identification of genes associated with psoriasis in
genetic studies
We identified 117 candidate genes from psoriasis GWAS
studies based upon entries from the National Human
Genome Research Institute (NHGRI) GWAS catalogue
[32] and a recent psoriasis GWAS meta-analysis [26].
We first identified 44 entries associated with the disease
trait “Psoriasis” in the NHGRI GWAS catalogue [32].
Genes associated with these entries included those repor-
tedly associated with each SNP in the source study as well
as any genes immediately upstream or downstream (i.e.,
database columns “Reported Genes”, “Upstream_gene_id”
and “Downstream_gene_id”). Additionally, we analyzed
the chromosomal location for each entry and identified
any genes overlapping with this location, the most
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stream gene. Altogether, we identified 77 unique candidate
genes associated with 44 entries from the NHGRI GWAS
catalogue [32].
Second, we analyzed 36 loci identified from a recent
psoriasis GWAS meta-analysis [26]. Candidate genes
associated with these loci included the “notable genes”
listed in Table one from Tsoi et al. [26], any genes over-
lapping the lead SNP, and genes immediately upstream
or downstream from the lead SNP. This yielded 101
unique candidate genes associated with 36 loci.
We pooled the 77 candidates identified from the
NHGRI GWAS catalogue with the 101 candidates iden-
tified in the GWAS meta-analysis. After removing dupli-
cates from both sources, there remained 129 unique
genes. Of these, 117 were represented by a probe set fea-
ture on the Affymetrix Human Genome U133 Plus 2.0
array and were thus considered in our analyses of psoria-
sis GWAS candidates.
Additional analyses were performed based upon 357
genes included in the Human Genome Epidemiology
Network (HuGENet) database (Additional files 13 and 14)
[33]. This gene set is more comprehensive than that dis-
cussed above, since it includes genes associated with pso-
riasis in GWAS studies, as well as genes linked to
psoriasis in non-GWAS epidemiologic population-based
studies [33]. The “Phenopedia” file was downloaded from
the HuGENet website (October 2013) and we identified
395 unique human genes associated with the disease
identifier “Psoriasis(C0033860)”. Of these 395 genes, 357
were represented by a probe set feature included on the
Affymetrix Human Genome U133 Plus 2.0 array and were
thus included in our analyses (Additional files 13 and 14).
Analysis of susceptibility-associated variation near
intergenic (non-coding) psoriasis susceptibility loci
We analyzed susceptibility-associated variation near six
intergenic (non-coding) susceptibility loci identified from
a recent psoriasis GWAS meta-analysis (Figures 7 and 8
and Additional file 16) [26]. In each case, we first identi-
fied a suspected target gene near the susceptibility locus
(i.e., TNFRSF9, B3GNT2, IL12B, TAGAP, KLF4 or
NFKBIA). The cell type for which the target gene’s median
expression was highest was assigned as the candidate cell
type (Figure 7A). Given this cell type, we identified the
local co-expression network for the target gene, consisting
of the N genes most strongly co-expressed with the target
gene (Spearman correlation coefficient, rs). The cut-off
value of N was chosen based upon the steepness with
which rs estimates declined across the set of genes (with
rs > 0) that had been ranked in descending order according
to rs estimates (Figure 7B). The chosen value of N was de-
termined by identifying the bending point or “knee” in this
curve, corresponding the point at which distance betweenthe curve and the origin of the plot is minimized
(Figure 7B) [81,82]. Once the local co-expression network
for the suspected target gene had been identified, in-
tergenic sequences adjacent to genes within this co-
expression network were analyzed to identify DNA motifs
present with significantly elevated frequency [81].
We compiled a dictionary of 1937 motifs, where each
motif represented the experimentally-determined bin-
ding preference of a human TF or DNA-binding protein.
Motifs were obtained by pooling collections from five
sources (i.e., Jaspar, UniPROBE, ENCODE, hPDI and
TRANSFAC) [83-87], as described in a recent publi-
cation [65]. To identify motif matches in the human gen-
ome, intergenic sequences were scanned with masking of
repetitive DNA elements and assembly gaps (R package:
BSgenome.Hsapiens.UCSC.hg19). A position weight ma-
trix (PWM) was evaluated for each motif, with a genome
match declared at any locus for which the PWM score
exceeded 80% of the maximum match score for that
PWM (R function: matchPWM, R package: Biostrings).
PWM matches were assessed using empirically-deter-
mined nucleotide background frequencies estimated from
intergenic regions in the human genome (0.30, 0.20, 0.20,
0.30 for A, C, G and T, respectively). For each intergenic
sequence, forward and reverse strands were scanned in 5’
to 3’ orientation, and the total number of PWM matches
for any sequence was equal to the number of matches on
both strands (any overlapping matches were merged and
not double-counted). For each motif, the number of
matches was compared between a foreground set of inter-
genic sequences (adjacent to the N genes within the co-
expression network) and a background set of intergenic
sequences (adjacent to genes with detectable expression in
the candidate cell type excluding sequences adjacent to
the N genes within the co-expression network). Significant
enrichment with respect to foreground sequences was
assessed using semiparametric generalized additive logistic
models [81]. Based on this analysis, we identified motifs
significantly associated with co-expression networks for
the putative target gene and ranked all motifs according to
the strength of this association.
For each of the six intergenic loci, we identified SNPs in
linkage disequilibrium with the lead SNP identified in the
prior GWAS meta-analysis (r2 > 0.90) [26]. To identify
linked SNPs, variant call format (vcf) files were down-
loaded from the 1000 Genomes project (phase 1) and con-
verted to PLINK input files (EUR subpopulation). PLINK
was then used to identify all SNPs in linkage disequilib-
rium with the lead SNP (r2 > 0.90) (i.e., the –ld-snp com-
mand option) [88]. We inspected linked SNPs to identify
those at which variation engendered or abrogated a match
to one of the 1937 motifs included in our dictionary. Con-
sistent with the above-stated criterion, a motif match for a
SNP locus was called if the PWM score exceeded 80% of
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or reverse strand (R function: matchPWM, R package:
Biostrings). This yielded SNP-motif pairs for which gene-
tic variation was predicted to influence TF binding. SNP-
motif pairs were then ranked by the degree to which the
motif showed enrichment among sequences adjacent to
genes belonging to the target gene’s co-expression net-
work (Figure 8A).
Analysis of TNFRSF9 mRNA and protein expression
Human KCs and immune cell subsets were obtained from
healthy human volunteers using a published protocol [89].
Lesional, uninvolved and healthy control skin was obtained
and processed as described [90]. RNA was extracted using
RNeasy columns (Qiagen, Cat No. 74104) and evaluated
using the Agilent 2100 Bioanalyzer. A commercial kit was
used for reverse transcription (Applied Biosystems, Cat No.
4368814). QRT-PCR was done with primers for TNFRSF9
(Applied Biosystems, Cat No. Hs00155512_m1) and RPLP0
(Applied Biosystems, Cat No. Hs99999902_m1) using the
7990HT Fast Real-Time PCR system (Applied Biosys-
tems). Whole blood was obtained from healthy donors
and analyzed by flow cytometry for cell surface TNFRSF9
(Biolegend, Cat. No. 309810), anti-CD15 (BioLegend, Cat
No. 323022), anti-CD3 (BioLegend, Cat No. 344808) and
anti-CD14 (BD Pharmingen, Cat. No. 555397). Samples
were analyzed using the LSR II flow cytometer (BD
Biosciences).
Additional files
Additional file 1: Genes significantly elevated in psoriasis lesions
(n = 216 patients). The table lists the 1019 differentially expressed genes
(DEGs) significantly elevated in psoriasis lesions (FC > 1.50, FDR < 0.05).
DEGs are sorted according to their median fold-change in lesional skin
as compared to uninvolved skin (n = 216 patients). The table lists the
frequency with which each gene was detected significantly above
background among PP samples (third column) and PN samples (fourth
column) (Wilcoxon signed rank test, P < 0.05). P-values for differential
expression were calculated using the Wilcoxon rank sum test (fifth column)
and FDR-adjusted p-values were calculated using the Benjamini-Hochberg
method (final column).
Additional file 2: Genes significantly decreased in psoriasis lesions
(n = 216 patients). The table lists the 885 differentially expressed genes
(DEGs) significantly decreased in psoriasis lesions (FC < 0.67, FDR < 0.05).
DEGs are sorted according to their median fold-change in lesional skin
as compared to uninvolved skin (n = 216 patients). The table lists the
frequency with which each gene was detected significantly above
background among PP samples (third column) and PN samples (fourth
column) (Wilcoxon signed rank test, P < 0.05). P-values for differential
expression were calculated using the Wilcoxon rank sum test (fifth column)
and FDR-adjusted p-values were calculated using the Benjamini-Hochberg
method (final column).
Additional file 3: Psoriasis DEGs are (on average) detected in most
(>84%) PP and PN skin samples (P ≤ 0.02). Figures (A) – (D) show the
average detection frequency of psoriasis DEGs (black arrow) as compared to
a null distribution generated by random sampling from all skin-expressed
genes. (A) The 1019 PP-increased DEGs were detected in 94.5% of PP
samples on average. This percentage value was significantly larger than
expected based upon 10000 random samples of 1019 genes. (B) The 1019PP-increased DEGs were detected in 84.1% of PN samples on average
(P = 0.02, 10000 random samples of 1019 genes). (C) The 885 PP-decreased
DEGs were detected in 86.5% of PP samples on average (P < 0.001, 10000
random samples of 885 genes). (D) The 885 PP-decreased DEGs were
detected in 94.5% of PN samples on average (P < 0.001, 10000 random
samples of 885 genes).
Additional file 4: Gene set enrichment analysis: Psoriasis DEGs
overlap significantly with genes altered in various skin conditions,
cytokine-treated KCs, and RNAi-treated KCs. (A) Comparison with
skin diseases. Expanded results from Figure 1A with the top-ranked 30
comparisons (of 51 included in our screen). (B) Comparison with
cytokine-treated KCs. Expanded results from Figure 1B with the top-ranked
30 comparisons (of 46 included in our screen). (C) RNAi experiments. Ranked
gene lists were generated from experiments in which microarrays were
used to evaluate gene expression in KCs following RNAi. The RNAi target is
listed in the label for each experiment (left margin). In both (B) and (C), one
asterisk (*) denotes experiments performed with HaCaT KCs, while two
asterisks (**) denotes experiments performed using reconstituted epidermis.
All other experiments were performed with primary NHEKs.
Additional file 5: Number of microarray samples analyzed for each
cell type. The table lists the number of microarray samples initially
considered for each cell type, as well as the number of microarray
samples remaining following quality control checks (post-QC). All samples
were generated using same oligonucleotide microarray platform
(Affymetrix Human Genome U133 Plus 2.0 Array). Analyses are based only
upon the post-QC samples that survived the quality control filtering
(final column on right). GEO series accession ids associated with post-QC
samples are listed below the table, with the number of samples from
each GEO series listed in parentheses.
Additional file 6: Genes assigned to each of 10 cell types show bias
towards PP-increased or PP-decreased expression. (A) The 16358
skin-expressed genes were ranked according to the estimated median
PP/PN fold-change (n = 216 patients, horizontal axis). For each cell type,
the line tracks the cumulative overlap between top-ranked genes and
the set of genes assigned to that cell type. The area calculated for each
cell type represents the region between the diagonal line (random
expectation) and the line drawn for each cell type, respectively. P-values
were generated from the Wilcoxon rank sum test. (B) The same analysis was
repeated, except only genes showing a cell type-specific expression pattern
were included, with expression in the assigned cell type significantly higher
than expression in each of the other 9 cell types (FDR < 0.05; Wilcoxon rank
sum test).
Additional file 7: PP-increased DEGs show aberrantly high
expression in KCs and macrophages. We identified 1019 PP-increased
DEGs (median FC > 1.50, FDR < 0.05; Wilcoxon rank sum test; n = 216
patients). The average detection frequency among the 1019 DEGs was
calculated for each cell type (black arrows, left column). Likewise, the
median expression among the 1019 DEGs was calculated with respect to
each cell type (black arrows, right column). Null distributions for the
average detection frequency and median expression level were generated
based upon 10000 samples of 1019 genes chosen randomly from 16358
skin-expressed genes. P-values were calculated using these empirical null
distributions and are shown in the figure. Expression values (right
column) are normalized to normal human skin, such that values greater
than 1 indicate that expression is greater than that in normal skin, while
values less than 1 indicate that expression is lower than that in normal skin.
Additional file 8: Top 30 genes most strongly elevated in psoriasis
lesions (n = 216 patients) and their expression across 10 cell types.
The table lists the 30 DEGs most strongly elevated in psoriasis lesions
(i.e., highest median PP/PN fold-change, with FDR < 0.05). The color scale
denotes median expression of each gene, as compared to the gene’s
median expression in normal human skin. Red colors thus denote
expression that is higher in comparison to normal human skin, while
blue colors indicate that expression is lower in comparison to normal
human skin. For each gene and cell type, black circles indicate the
percentage of microarray samples for which the gene’s expression was
detected above background (P < 0.05, Wilcoxon signed-rank test). The
cell type assigned to each gene is listed in the right margin. Magenta
labels denote cases in which the gene’s expression in the assigned cell
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types (FDR < 0.05, Wilcoxon rank sum test).
Additional file 9: Psoriasis lesions from 216 patients vary with
respect to the expression of genes specifically expressed by
immune cell types. Cell type-specific signature scores were calculated
for each patient and each cell type. Signature scores for a cell type were
calculated based upon a set of 250 genes with high expression in that
cell type (as compared to the other 9 cell types), with scores equal to the
weighted average of fold-change values (PP/PN) among the 250 genes
for a given patient (weighted arithmetic mean). Genes showing the most
cell type-specific expression pattern were assigned the greatest weight in
these calculations. Patients were then clustered based upon signature
scores across the 10 cell types (Euclidean distance with complete linkage).
Values in the bottom margin indicate the percentage of patients for which
signature scores were significantly large (red, P < 0.05) or significantly small
(blue, P < 0.05). Significance of scores was evaluated based upon whether
PP/PN fold-changes for the 250 signature genes differed from those of all
other skin-expressed genes (Wilcoxon rank sum test). Patients were assigned
to one of three groups based upon the patterns observed for immune cell
types (weak inflammation, 67/216; moderate inflammation, 104/216; strong
inflammation, 45/216).
Additional file 10: PP-decreased DEGs show aberrantly low
expression in all cell types except fibroblasts. We identified 885
PP-decreased DEGs (median FC > 1.50, FDR < 0.05; Wilcoxon rank sum test;
n = 216 patients). The average detection frequency among the 885 DEGs
was calculated for each cell type (black arrows, left column). Likewise, the
median expression among the 885 DEGs was calculated with respect to
each cell type (black arrows, right column). Null distributions for the average
detection frequency and median expression level were generated based
upon 10000 samples of 885 genes chosen randomly from 16358 skin-
expressed genes. P-values were calculated using these empirical null
distributions and are shown in the figure. Expression values (right column)
are normalized to normal human skin, such that values greater than 1
indicate that expression is greater than that in normal skin, while values less
than 1 indicate that expression is lower than that in normal skin.
Additional file 11: Top 30 genes most strongly decreased in
psoriasis lesions (n = 216 patients) and their expression across 10
cell types. The table lists the 30 DEGs most strongly decreased in
psoriasis lesions (i.e., lowest median PP/PN fold-change, with FDR < 0.05).
The color scale denotes median expression of each gene, as compared
to the gene’s median expression in normal human skin. Red colors thus
denote expression that is high in comparison to normal human skin,
while blue colors indicate that expression is low in comparison to normal
human skin. For each gene and cell type, black circles indicate the
percentage of microarray samples for which the gene’s expression was
detected above background (Wilcoxon signed-rank test; P < 0.05). The cell
type assigned to each gene is listed in the right margin. This is the cell
type for which the gene’s median expression level was the highest,
provided that the gene’s detection frequency for that cell type was
greater than 10%. Magenta labels denote cases in which the gene’s
expression in the assigned cell type is significantly higher than its
expression in each of the other 9 cell types, respectively (FDR < 0.05,
Wilcoxon rank sum test).
Additional file 12: Candidate genes from psoriasis GWAS studies
show aberrantly high expression in immune cell populations. We
identified 117 candidate genes near GWAS loci. The average detection
frequency among these 117 genes was calculated for each cell type (black
arrows, left column). Likewise, the median expression among the 117 genes
was calculated with respect to each cell type (black arrows, right column).
Null distributions for the average detection frequency and median
expression level were generated based upon 10000 samples of 117 genes
chosen randomly from the 20184 human genes represented on the
Affymetrix Human Genome U133 Plus 2.0 array. P-values were calculated
using these empirical null distributions and are shown in the figure.
Expression values (right column) are normalized to normal human skin, such
that values greater than 1 indicate that expression is greater than that in
normal skin, while values less than 1 indicate that expression is lower than
that in normal skin.Additional file 13: Assignment of gene candidates from genetic
studies to cell types present in lesional skin (HuGENet database).
Human genes were assigned to one of 10 cell types present in psoriasis
lesions (see Results and Methods). Top: Analysis of 357 genes associated
with psoriasis in either GWAS or non-GWAS population-based studies
(HuGENet database). Bottom: Combined analysis of the 357 genes
associated with psoriasis from the HuGENet database and the set of 117
GWAS-only gene candidates (439 unique genes total). Magenta labels
denote those cell types for which the number of assigned genes was
significantly large in comparison to known human genes (i.e., all genes
represented on the Affymetrix Human Genome U133 Plus 2.0 array
platform) (one asterisk, P < 0.05; two asterisks, FDR < 0.05; Fisher’s Exact Test).
Additional file 14: Cluster analysis of 439 genes genetically
associated with psoriasis in population-based genetic studies and
their expression across 10 cell types. We identified 117 genes near
candidate loci identified from GWAS studies and combined these with a
set of 357 genes associated with psoriasis (GWAS or non-GWAS studies)
in the HuGENet database (439 genes total). These genes were clustered
based upon their expression pattern across 10 cell types (Euclidean
distance and average linkage). The red-blue heatmap shows the
expression of genes in each cell type, with red colors indicating relatively
high expression (compared to normal human skin) and blue colors
indicating relatively low expression (compared to normal human skin).
The yellow-black heatmap shows the cell type assigned to each gene
(i.e., the cell type for which the gene’s median expression was highest,
with detection frequency greater than 10%). The chart on the far right
shows the estimated median fold-change (PP/PN) for each gene (n = 216
patients).
Additional file 15: TNFRSF9 mRNA is elevated in psoriasis lesions
and TNFRSF9 mRNA and protein levels are highest in neutrophils as
compared to other cell types. (A) TNFRSF9 mRNA expression in five cell
types (n > 4 for each cell type). (B) TNFRSF9 mRNA is significantly elevated
in psoriasis lesions as compared to uninvolved and normal skin (n = 11).
(C) TNFRS9 (CD137) protein expression is highest in neutrophils as
compared to T-cells and monocytes isolated from the peripheral blood.
(D) Flow cytometric analysis shows TNFRSF9-positive neutrophils over
isotype control (negative cells). In parts (A) – (C), expression is normalized to
the housekeeping gene large ribosomal protein P0 (RPLP0). Bars represent
mean ± 1SD (*P < 0.05, **P < 0.01, ***P < 0.001).
Additional file 16: Identification and prioritization of transcription
factor binding sites sensitive to susceptibility-associated variation
near psoriasis intergenic risk loci. Procedures outlined in Figures 7 and
8 were repeated with respect to six genes near intergenic risk loci
(TNFRSF9, B3GNT2, IL12B, TAGAP, KLF4 and NFKBIA). Top: Expression of each
gene was evaluated across 10 cell types (n = 50 microarray samples per
cell type). Expression is normalized to that observed in normal human
skin and values in yellow denote the gene’s detection frequency. The
candidate cell type for each gene is shown in magenta font. Bottom:
Top 10 binding sites most strongly enriched among sequences near
co-expressed genes identified with respect to the candidate cell type.
The listed binding sites include only those that are sensitive to variation
at a SNP locus in linkage disequilibrium with the lead SNP (r2 > 0.90). The
chart shows the Z statistic quantifying the degree to which each binding
site is enriched among sequences adjacent to co-expressed genes.
Associated p-values are listed in the left margin, where an asterisk symbol
is used to denote FDR < 0.05. The right margin lists the SNP for which
variation is predicted to influence binding. Blue font denotes binding
sites for which the risk variant abrogates a match to the binding site,
while red font denotes binding sites for which the risk variant engenders
a match to the binding site.
Additional file 17: Demographic data and washout protocols for
psoriasis microarray cohorts. The table lists the number of patient
samples included from each of the eight microarray studies (n). The table
also lists known demographic data on each patient cohort and the
disease severity of patients admitted into each study. The final two
columns indicate reported washout protocols. This represents the period
of time for which participants discontinued systemic or topical
medications prior to biopsy collections. In some cases, information was
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Additional file 18: Quality control (QC) processing of psoriasis
microarray data. The dataset was generated by pooling samples across
8 prior studies (GSE13355, GSE14905, GSE30999, GSE34248, GSE41662,
GSE41663, GSE47751 and GSE50790), which yielded an initial set of 458
paired PP and PN samples from 229 patients. All samples were generated
using the same commercial microarray platform (Affymetrix Human
Genome U133 Plus 2.0 array). The 458 samples were evaluated with
respect to (A) Average background, (B) Scale factor, (C) RNA degradation
score, (D) Percentage of probe sets called present, (E) NUSE median,
(F) NUSE IQR, (G) RLE median and (H) RLE IQR. Parts (A) – (H) show QC
results for each of these metrics with respect to each dataset individually
(top) as well as the combination across all datasets (bottom). Yellow
symbols represent microarray samples excluded on the basis of QC
criteria. Following these steps, there remained 434 samples from 217
patients. (I) For the remaining patients, we calculated the average
fold-change among 434 genes with strongly elevated expression (median
FC > 2.0 and FDR < 0.05; n = 217), and the average fold-change among
194 genes with strongly repressed expression (median FC < 0.50 and
FDR < 0.05; n = 217). This revealed one outlier patient with trends
opposite to those expected. The patient was thus removed from the
dataset, yielding 432 samples from 216 patients. (J) The 216 remaining
patients were clustered based upon PP versus PN differences observed
for 16358 skin-expressed genes (Euclidean distance metric with complete
linkage).
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